IBIO iBio, Inc.

NYSE ibioinc.com


$ 1.06 $ 0.05 (5.5 %)    

Friday, 21-Nov-2025 14:19:50 EST
QQQ $ 596.58 $ 9.25 (1.57 %)
DIA $ 465.43 $ 5.96 (1.3 %)
SPY $ 664.22 $ 9.22 (1.41 %)
TLT $ 89.36 $ -0.30 (-0.33 %)
GLD $ 376.17 $ 2.18 (0.58 %)
$ 0.9951
$ 0.98
$ 1.04 x 300
$ 1.06 x 500
$ 0.96 - $ 1.06
$ 0.56 - $ 6.89
1,036,373
na
22.38M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 09-05-2025 06-30-2025 10-K
3 05-02-2025 03-31-2025 10-Q
4 02-10-2025 12-31-2024 10-Q
5 11-12-2024 09-30-2024 10-Q
6 09-20-2024 06-30-2024 10-K
7 05-13-2024 03-31-2024 10-Q
8 02-09-2024 12-31-2023 10-Q
9 11-14-2023 09-30-2023 10-Q
10 09-27-2023 06-30-2023 10-K
11 05-15-2023 03-31-2023 10-Q
12 02-14-2023 12-31-2022 10-Q
13 11-14-2022 09-30-2022 10-Q
14 10-11-2022 06-30-2022 10-K
15 05-12-2022 03-31-2022 10-Q
16 02-14-2022 12-31-2021 10-Q
17 11-15-2021 09-30-2021 10-Q
18 09-28-2021 06-30-2021 10-K
19 05-17-2021 03-31-2021 10-Q
20 02-16-2021 12-31-2020 10-Q
21 11-16-2020 09-30-2020 10-Q
22 10-13-2020 06-30-2020 10-K
23 05-15-2020 03-31-2020 10-Q
24 02-14-2020 12-31-2019 10-Q
25 11-14-2019 09-30-2019 10-Q
26 08-26-2019 06-30-2019 10-K
27 05-10-2019 03-31-2019 10-Q
28 02-13-2019 12-31-2018 10-Q
29 11-13-2018 09-30-2018 10-Q
30 09-18-2018 06-30-2018 10-K
31 05-11-2018 03-31-2018 10-Q
32 02-14-2018 12-31-2017 10-Q
33 11-09-2017 09-30-2017 10-Q
34 09-15-2017 06-30-2017 10-K
35 05-15-2017 03-31-2017 10-Q
36 02-21-2017 12-31-2016 10-Q
37 11-18-2016 09-30-2016 10-Q
38 10-13-2016 06-30-2016 10-K
39 05-23-2016 03-31-2016 10-Q
40 02-22-2016 12-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ibio-q1-eps-011-misses-010-estimate-sales-100000k-beat-25000k-estimate

iBio (AMEX:IBIO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 7.84 ...

 ibio-announces-new-preclinical-data-from-obese-nhp-study-evaluating-ibio-610-activin-e-antibody-candidate-supported-by-preclinical-data

Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic we...

 why-did-ibio-shares-surge-over-11-in-pre-market-trading

iBio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry conferences.

 oppenheimer-initiates-coverage-on-ibio-with-outperform-rating-announces-price-target-of-5

Oppenheimer analyst Jay Olson initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target o...

 leerink-partners-initiates-coverage-on-ibio-with-outperform-rating-announces-price-target-of-2

Leerink Partners analyst Roanna Ruiz initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price T...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION